Neurotrophin-3 (NT-3) as a Potential Biomarker of the Peripheral Nervous System Damage Following Breast Cancer Treatment
Damage to the peripheral nervous system (PNS) is a common complication of breast cancer (BC) treatment, with 60 to 80% of breast cancer survivors experiencing symptoms of PNS damage. In the current study, the levels of brain-derived neurotrophic factor (BDNF), galectin-3 (Gal-3), and neurotrophin-3...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Pathophysiology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1873-149X/30/2/10 |
| _version_ | 1797593097020899328 |
|---|---|
| author | Samvel Tonyan Maria Pospelova Varvara Krasnikova Olga Fionik Tatyana Alekseeva Konstantin Samochernykh Nataliya Ivanova Tatyana Vavilova Elena Vasilieva Albina Makhanova Aleksandra Nikolaeva Tatyana Bukkieva Stephanie Combs Maxim Shevtsov |
| author_facet | Samvel Tonyan Maria Pospelova Varvara Krasnikova Olga Fionik Tatyana Alekseeva Konstantin Samochernykh Nataliya Ivanova Tatyana Vavilova Elena Vasilieva Albina Makhanova Aleksandra Nikolaeva Tatyana Bukkieva Stephanie Combs Maxim Shevtsov |
| author_sort | Samvel Tonyan |
| collection | DOAJ |
| description | Damage to the peripheral nervous system (PNS) is a common complication of breast cancer (BC) treatment, with 60 to 80% of breast cancer survivors experiencing symptoms of PNS damage. In the current study, the levels of brain-derived neurotrophic factor (BDNF), galectin-3 (Gal-3), and neurotrophin-3 (NT-3) were measured in the blood serum of BC patients by ELISA as potential biomarkers that might indicate the PNS damage. Sixty-seven patients were enrolled in this multi-center trial and compared to the aged-matched healthy female volunteers (control group) (<i>n</i> = 25). Intergroup comparison of biomarker levels (i.e., Gal-3 and BDNF) did not show significant differences in any of the studied subgroups. However, intriguingly, NT-3 levels were significantly higher in BC patients as compared to healthy volunteers, constituting 14.85 [10.3; 18.0] and 5.74 [4.56; 13.7] pg/mL, respectively (<i>p</i> < 0.001). In conclusion, NT-3 might be employed as a potential biomarker in BC patients with clinical manifestations of PNS damage. However, further studies to validate its correlation to the degree of peripheral nervous system lesions are of high value. |
| first_indexed | 2024-03-11T02:03:57Z |
| format | Article |
| id | doaj.art-2393e52fe8b446be8f0e715f82d6b3c2 |
| institution | Directory Open Access Journal |
| issn | 1873-149X |
| language | English |
| last_indexed | 2024-03-11T02:03:57Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pathophysiology |
| spelling | doaj.art-2393e52fe8b446be8f0e715f82d6b3c22023-11-18T12:00:55ZengMDPI AGPathophysiology1873-149X2023-04-0130211012210.3390/pathophysiology30020010Neurotrophin-3 (NT-3) as a Potential Biomarker of the Peripheral Nervous System Damage Following Breast Cancer TreatmentSamvel Tonyan0Maria Pospelova1Varvara Krasnikova2Olga Fionik3Tatyana Alekseeva4Konstantin Samochernykh5Nataliya Ivanova6Tatyana Vavilova7Elena Vasilieva8Albina Makhanova9Aleksandra Nikolaeva10Tatyana Bukkieva11Stephanie Combs12Maxim Shevtsov13Personalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaDepartment of Radiation Oncology, Technishe Universität München (TUM), Klinikum Rechts der Isar, Ismaninger Str. 22, 81675 Munich, GermanyPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaDamage to the peripheral nervous system (PNS) is a common complication of breast cancer (BC) treatment, with 60 to 80% of breast cancer survivors experiencing symptoms of PNS damage. In the current study, the levels of brain-derived neurotrophic factor (BDNF), galectin-3 (Gal-3), and neurotrophin-3 (NT-3) were measured in the blood serum of BC patients by ELISA as potential biomarkers that might indicate the PNS damage. Sixty-seven patients were enrolled in this multi-center trial and compared to the aged-matched healthy female volunteers (control group) (<i>n</i> = 25). Intergroup comparison of biomarker levels (i.e., Gal-3 and BDNF) did not show significant differences in any of the studied subgroups. However, intriguingly, NT-3 levels were significantly higher in BC patients as compared to healthy volunteers, constituting 14.85 [10.3; 18.0] and 5.74 [4.56; 13.7] pg/mL, respectively (<i>p</i> < 0.001). In conclusion, NT-3 might be employed as a potential biomarker in BC patients with clinical manifestations of PNS damage. However, further studies to validate its correlation to the degree of peripheral nervous system lesions are of high value.https://www.mdpi.com/1873-149X/30/2/10peripheral nervous systemneuropathypostmastectomy pain syndromechemotherapy-induced peripheral neuropathyradiation-induced peripheral neuropathybrain-derived neurotrophic factor |
| spellingShingle | Samvel Tonyan Maria Pospelova Varvara Krasnikova Olga Fionik Tatyana Alekseeva Konstantin Samochernykh Nataliya Ivanova Tatyana Vavilova Elena Vasilieva Albina Makhanova Aleksandra Nikolaeva Tatyana Bukkieva Stephanie Combs Maxim Shevtsov Neurotrophin-3 (NT-3) as a Potential Biomarker of the Peripheral Nervous System Damage Following Breast Cancer Treatment Pathophysiology peripheral nervous system neuropathy postmastectomy pain syndrome chemotherapy-induced peripheral neuropathy radiation-induced peripheral neuropathy brain-derived neurotrophic factor |
| title | Neurotrophin-3 (NT-3) as a Potential Biomarker of the Peripheral Nervous System Damage Following Breast Cancer Treatment |
| title_full | Neurotrophin-3 (NT-3) as a Potential Biomarker of the Peripheral Nervous System Damage Following Breast Cancer Treatment |
| title_fullStr | Neurotrophin-3 (NT-3) as a Potential Biomarker of the Peripheral Nervous System Damage Following Breast Cancer Treatment |
| title_full_unstemmed | Neurotrophin-3 (NT-3) as a Potential Biomarker of the Peripheral Nervous System Damage Following Breast Cancer Treatment |
| title_short | Neurotrophin-3 (NT-3) as a Potential Biomarker of the Peripheral Nervous System Damage Following Breast Cancer Treatment |
| title_sort | neurotrophin 3 nt 3 as a potential biomarker of the peripheral nervous system damage following breast cancer treatment |
| topic | peripheral nervous system neuropathy postmastectomy pain syndrome chemotherapy-induced peripheral neuropathy radiation-induced peripheral neuropathy brain-derived neurotrophic factor |
| url | https://www.mdpi.com/1873-149X/30/2/10 |
| work_keys_str_mv | AT samveltonyan neurotrophin3nt3asapotentialbiomarkeroftheperipheralnervoussystemdamagefollowingbreastcancertreatment AT mariapospelova neurotrophin3nt3asapotentialbiomarkeroftheperipheralnervoussystemdamagefollowingbreastcancertreatment AT varvarakrasnikova neurotrophin3nt3asapotentialbiomarkeroftheperipheralnervoussystemdamagefollowingbreastcancertreatment AT olgafionik neurotrophin3nt3asapotentialbiomarkeroftheperipheralnervoussystemdamagefollowingbreastcancertreatment AT tatyanaalekseeva neurotrophin3nt3asapotentialbiomarkeroftheperipheralnervoussystemdamagefollowingbreastcancertreatment AT konstantinsamochernykh neurotrophin3nt3asapotentialbiomarkeroftheperipheralnervoussystemdamagefollowingbreastcancertreatment AT nataliyaivanova neurotrophin3nt3asapotentialbiomarkeroftheperipheralnervoussystemdamagefollowingbreastcancertreatment AT tatyanavavilova neurotrophin3nt3asapotentialbiomarkeroftheperipheralnervoussystemdamagefollowingbreastcancertreatment AT elenavasilieva neurotrophin3nt3asapotentialbiomarkeroftheperipheralnervoussystemdamagefollowingbreastcancertreatment AT albinamakhanova neurotrophin3nt3asapotentialbiomarkeroftheperipheralnervoussystemdamagefollowingbreastcancertreatment AT aleksandranikolaeva neurotrophin3nt3asapotentialbiomarkeroftheperipheralnervoussystemdamagefollowingbreastcancertreatment AT tatyanabukkieva neurotrophin3nt3asapotentialbiomarkeroftheperipheralnervoussystemdamagefollowingbreastcancertreatment AT stephaniecombs neurotrophin3nt3asapotentialbiomarkeroftheperipheralnervoussystemdamagefollowingbreastcancertreatment AT maximshevtsov neurotrophin3nt3asapotentialbiomarkeroftheperipheralnervoussystemdamagefollowingbreastcancertreatment |